Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins  by Marblestone, Jeffrey G. et al.
Biochimica et Biophysica Acta 1823 (2012) 2094–2097
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrAnalysis of ubiquitin E3 ligase activity using selective polyubiquitin
binding proteins☆
Jeffrey G. Marblestone ⁎, James P. LaRocque, Michael R. Mattern, Craig A. Leach
Progenra Inc., 277 Great Valley Parkway, Malvern, PA 19355, USA☆ This article is part of a Special Issue entitled: U
Diagnostics.
⁎ Corresponding author. Tel.: +1 610 644 6974; fax:
E-mail address: Marblestone@progenra.com (J.G. Ma
0167-4889/$ – see front matter © 2012 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2012.06.013a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 April 2012
Received in revised form 11 June 2012
Accepted 12 June 2012







Drug discoveryThe ubiquitin proteasome pathway controls the cellular degradation of ~80–90% of the proteome in a highly
regulated manner. In this pathway, E3 ligases are responsible for the conjugation of ubiquitin to protein sub-
strates which can lead to their destruction by the 26S proteasome. Aberrant E3 ligases have been implicated
in several diseases and are widely recognized as attractive targets for drug discovery. As researchers continue
to characterize E3 ligases, additional associations with various disease states are being exposed. The availabil-
ity of assays that allow rapid analysis of E3 ligase activity is paramount to both biochemical studies and drug
discovery efforts aimed at E3 ligases. To address this need, we have developed a homogenous assay for mon-
itoring ubiquitin chain formation using Tandem Ubiquitin Binding Entities (TUBEs). TUBEs bind selectively to
polyubiquitin chains versus mono-ubiquitin thus enabling the detection of polyubiquitin chains in the pres-
ence of mono-ubiquitin. This assay reports on the proximity between the protein substrate and TUBEs as a
result of polyubiquitin chain formation by an E3 ligase. This homogenous assay is a step forward in
streamlining an approach for characterizing and quantitating E3 ligase activity in a rapid and cost effective
manner. This article is part of a Special Issue entitled: Ubiquitin Drug Discovery and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Ubiquitylation is a post translational modiﬁcation that controls
many aspects of cellular physiology. Ubiquitin (Ub) is a 76 amino
acid polypeptide that is conjugated to target proteins and affects a
protein's cellular role in a myriad of ways. The original and most
widely studied role for ubiquitin is its involvement in a protein's sta-
bility; however it is also involved in regulating protein localization,
oligomerization, activity, and function [1–3]. Ubiquitin modiﬁcations
play a complex role in the cell, and new technologies are needed for
dissecting and understanding these functions.
The conjugation of ubiquitin to a substrate protein involves a se-
quential three step enzymatic cascade that covalently attaches the
C-terminal glycine residue of ubiquitin to an amine group, typically
a lysine residue [4]. First, an E1 activating enzyme activates
ubiquitin's C-terminus in an ATP-dependent reaction. Next, the E1 in-
teracts and transfers the activated ubiquitin to an E2 conjugating en-
zyme, where the E2 forms a thioester bond with ubiquitin. Lastly, an
E3 ligase interacts with the E2–ubiquitin complex and a speciﬁc sub-
strate protein, enabling the transfer of ubiquitin to the substrate. A
substrate can be monoubiquitylated at a single lysine residue or
multi-monoubiquitylated at several lysine residues. Additionally, itbiquitin Drug Discovery and
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l rights reserved.is possible to form a polyubiquitin chain by attaching additional
ubiquitin molecules. There are seven lysine residues and the N-
terminal amino group present in ubiquitin which can be used for
chain assembly, each of which has a speciﬁc outcome.
Polyubiquitin chains on a target protein have been extensively
characterized and many have been shown to be directed to the
proteasome for degradation. The proteasome is a complex structure
which hydrolyses 80–90% of soluble proteins into short oligopeptides
and serves a critical role in cellular physiology [5]. The approval of
bortezomib (VELCADE), a proteasome inhibitor, for the treatment of
cancer, validated modulation of the ubiquitin pathway as an effective
therapeutic approach [6]. However, toxicities associated with
proteasome inhibition limit its clinical application. These toxicities
are most likely a result of the fact that proteasome inhibition will im-
pact the stability of thousands of proteins. In contrast, targeting en-
zymes upstream of the proteasome with small molecules should
impact a smaller population of proteins and will display less toxicity
than proteasome inhibition.
There are more than 600 predicted E3 ligases and each one is re-
sponsible for the ubiquitylation of a small number of proteins making
these enzymes attractive targets for the treatment of numerous path-
ological conditions. The complexity of the ubiquitin pathway has
made it challenging to develop technologies to readily study, charac-
terize and quantitate E3 ligase activity.
Tandem Ubiquitin Binding Entities (TUBEs) are linear fusions of
ubiquitin binding domains (UBAs) that bind polyubiquitin chains
with dissociation constants in the nanomolar range. The nanomolar
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tion of E3 ligase activity relative to free monomeric ubiquitin [7].
TUBEs are becoming established as one of the more versatile research
tools for the exploration of the ubiquitin pathway.
Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET)
detection was selected as the optimal means to quantitate the bind-
ing of TUBEs to the polyubiquitin chains as the product of the E3
ligase reaction. FRET is a technique that relies on proximity depen-
dent transfer of resonance energy from a donor ﬂuorophore to an ac-
ceptor ﬂuorophore. In FRET, a donor ﬂuorophore is excited by
incident light, and if an acceptor is in close proximity, the excited
state energy from the donor can be transferred [8]. Energy that is
emitted from a ﬂuorophore is characteristically in the form of light
at a speciﬁc wavelength. Because of this energy transfer, molecular
interactions between biomolecules can be assessed by coupling each
partner with a distinct ﬂuorescence label and detecting the level of
energy transfer. This method utilizes the validated TR-FRET lantha-
nide chemistry. The lanthanides have a long ﬂuorescence lifetime
and help avoid limitations associated with traditional FRET chemis-
tries, where background ﬂuorescence from sample components
such as buffers, proteins, chemical compounds and cell lysate inter-
feres with the ﬂuorescent readout. Lanthanide donor/acceptor pairs
have been optimized for qualitative and quantitative purposes,
which include spatial resolution, distance range, and sensitivity.
We applied TR-FRET and TUBEs to develop a novel, homogenous
E3 ligase activity assay. Speciﬁcally, we monitored the proximity of
the autoubiquitylated E3 ligase and our detection reagent, bio-
tinylated TUBEs in an E3 dependent polyubiquitin chain formation
assay (Fig. 1). It has previously been shown that HTRF® technology
(CisBio) is capable of detecting E3 ligase activity for a few E3 ligases,
such as Hdm2 and E6AP [9,10]. However, a key limitation associated
with this method in our view is the use of biotinylated ubiquitin. In
an approach that intentionally avoids altering ubiquitin and deviating
from its native structure, we use biotinylated TUBEs as our proximity
detection reagent. In this manner, we can use native ubiquitin and
TUBE detection to report on E3 dependent ubiquitin chain formation.
Herein, we will provide an analysis of how to quantitate E3 ligase
activity using TUBEs in a homogenous manner using CisBio HTRF®
technology. We evaluated time and dose dependency, and the homo-
geneous nature of this assay allows rapid proﬁling of E3 ligase activ-
ity. MuRF1 and TRIM25 were analyzed in this manner. MuRF1 is a
ubiquitin E3 ligase associated with muscle wasting, upregulated in
numerous atrophy models [11,12]. MuRF1 targets myoﬁbrillar pro-
teins for degradation and is itself a novel target to treat myopathy.
TRIM25 also demonstrated ubiquitylation activity in this assay.
TRIM25 is upregulated in response to estrogen, and it is thought to
mediate estrogen actions in breast cancer as a primary response
gene [13,14]. This novel assay was employed to study the activity of
these two E3 ligases.
2. Materials and methods
2.1. Materials
Unless stated otherwise, all reagents were obtained from Sigma
(St. Louis, MO) and were at a minimum of reagent grade or better.Fig. 1. Schematic model illustrating the hPlasmids encoding Ube1 and MuRF1 cDNAs were purchased from
Open Biosystems; while other vectors and proteins were generous
gifts (please see Acknowledgements).2.1.1. Cloning and protein expression
The cloning, expression, and puriﬁcation from BL21 (DE3) bacteria
of ubiquitin, 6his-Ube1, 6his-UbcH5c, GST-MuRF1, and GST-TRIM25
were performed using standard molecular biology techniques [15].
All constructs were fully sequenced to verify wildtype sequence.2.1.2. E3 ligase autoubiquitylation
Nunc 384-well white polypropylene microtiter plates (Thermo
Fisher Scientiﬁc) were used for autoubiquitylation assays. In a typical
assay, varying concentrations of an E3 ligase were incubated with
5 nM Ube1, 100 nM E2, 0.6 μM Ubiquitin, and 0.2 mM ATP in a 10 μl
reaction buffer (50 mM Tris–HCl, pH8.0, 5 mM MgCl2, and 1 mM
β-mercaptoethanol) in each well. After incubation at room
temperature for a ﬁxed period of time within the initial linear range
(15–30 min for MuRF1), detection reagents were added. E3
autoubiquitylation was detected by the addition of 10 nM bio-
tinylated TUBE1 (Lifesensors Inc.) and HTRF® detection ﬂuorophores
anti-GST K (cryptate) & Streptavidin-XL665 (phycobilliprotein pig-
ment) in detection buffer at a concentration recommended by the
manufacturer (1:500). The detection buffer contained potassium
ﬂuoride (KF), where the ﬁnal concentration was 800 mM in 20 μl.
The KF concentration used was determined to give greatest signal to
background (data not shown). Incubate for 1 h at room temperature.
The relative levels of ubiquitylated product were determined by an
increase in ﬂuorescence intensity using a ﬂuorescence plate reader
(Perkin Elmer Envision).2.1.3. Kinetic E3 ligase autoubiquitylation
Nunc 384-well white polypropylene microtiter plates (Thermo
Fisher Scientiﬁc) were used for autoubiquitylation assays. In a typical
assay, varying concentrations of an E3 ligase were incubated with
5 nM Ube1, 100 nM E2, 0.6 μM Ubiquitin, and 0.2 mM ATP in 50 mM
Tris–HCl, pH8.0, 5 mM MgCl2, and 1 mM β-mercaptoethanol in each
well with detection reagents. Detection reagents present were 1 nM
biotinylated TUBEs, 1 nM Streptavidin-Tb (Terbium donor), and
40 nM anti-GST D2 (acceptor) in a ﬁnal volume of 20 μl. Relative
levels of ubiquitylated product were determined by a ﬂuorescence
plate reader (Perkin Elmer Envision).2.1.4. Analyzing data in Excel
Using Microsoft Excel, CisBio's ratiometric calculation was applied
using raw data from the plate reader. HTRF® emission was measured
at two wavelengths, Em1:595/60 nm, Em2:665/7.5 nm using an exci-
tation wavelength of Ex: 340/60 nm. The HTRF® ratio is calculated
using the equation: Ratio=[(A665nm)/(B595nm)]×104. The multiply-
ing factor of 104 is used for the purpose of data handling. The ratio
for each well within an assay is calculated and the mean and standard
deviation of replicates determined using these values.omogenous E3 ligase assay platform.
Fig. 3. Dose dependent E3 ligase activity. Ubiquitylation reactions with increasing concen-
tration of the E3 ligase GST-MuRF1 correlate with an increased signal (Ratio) as detected in
our homogenous assay platform. Data are mean SD of triplicate determinations.
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3.1. Tandem ubiquitin binding domains recognize polyubiquitin chains
Previously, Ubiquitin Binding domains (UBAs) were employed to
capture polyubiquitin chains when immobilized in a 96-well plate
in a sandwich‐based ELISA protocol [16]. Hjerpe et al. demonstrated
that four linearly-fused UBAs appropriately named Tandem Ubiquitin
Binding Entities (TUBEs) efﬁciently bind polyubiquitin chains with
superior afﬁnity when compared to a single ubiquitin binding domain
[7]. To enhance throughput, we recognize that TUBEs need not be
immobilized, and can bind polyubiquitin chains freely in solution
[7]. TUBEs have outperformed single UBA domains, exhibiting a better
signal to background ratio in our assays and for this reason our cur-
rent assay focuses on the use of TUBEs in a homogenous E3 ligase
assay (data not shown).
We utilized CisBio's technology to monitor autoubiquitylation of
GST-tagged MuRF1 and TRIM25. A schematic model in Fig. 1 illus-
trates an E3 that undergoes autoubiquitylation in the presence of
E1, E2 enzymes, ubiquitin, and ATP. Biotinylated TUBE1 (LifeSensors
Inc.), added with a donor-labeled anti-GST antibody independently
binds to the reaction product. TUBEs bind the ubiquitin chain when
the GST-tagged E3 autoubiquitylates. Streptavidin-Acceptor (CisBio)
is added and adheres to the biotinylated-TUBE1, bringing the accep-
tor ﬂuorophore within close proximity of the donor-labeled antibody.
This proximity allows for the generation of a signal, following the ex-
citation of the donor ﬂuorophore; the magnitude is proportional to
the level of ubiquitylation.3.2. TUBEs detect E3 ligase dependent ubiquitylation
To test this assay, ubiquitin reactions consisted of a titration of
GST-MuRF1 (3–400 nM) with E1, E2, ATP and ubiquitin in a 10 μl re-
action. Detection reagents, TUBEs with anti-GST Europium and
Streptavidin-XL665 were then added at 2× their ﬁnal concentration.
Following that addition, the plates were incubated at room tempera-
ture for an hour and then read on a PerkinElmer Envision plate reader
with parameters recommended by CisBio. We used CisBio's rati-
ometric measurement to analyze and process our TR-FRET data. As
expected, MuRF1 autoubiquitylation was observed only when E1,
E2, MuRF1, ubiquitin, and ATP were present (Fig. 2). Fig. 3 demon-
strates that MuRF1 exhibited dose dependent polyubiquitylation.
These data demonstrate that this assay strategy can be used to mea-
sure E3-dependent ubiquitylation of proteins where the signal to
background is greater than 3.Fig. 2. Assessment of MuRF1 autoubiquitylation activity. Ubiquitylation reactions con-
ducted, where individual components (MuRF1, E1 (Ube1), E2 (UbcH5c), ubiquitin, and
ATP) are absent as noted. Data are mean SD of triplicate determinations.3.3. Kinetic evaluation of ubiquitylation with TUBEs
In Fig. 4, we demonstrate time and dose dependency with the E3
ligase TRIM25, read in real time. In this assay, we switched the
TR-FRET detection pair from Europium to Terbium (Tb) and XL665
to D2 after optimizing our protocol. In this format, FRET detection
can be read in the absence of KF. Streptavidin was also labeled with
the donor Tb instead of the acceptor. This minimized background in-
terference since a low amount of streptavidin is needed for the assay,
and therefore minimal amounts of Tb were used. The anti-GST anti-
body was then labeled with D2. This ﬁnal arrangement led to achiev-
ing better signal strength over background (~8 fold) and laid the
foundation for studying ubiquitylation kinetically.
In Fig. 4, various concentrations of GST-TRIM25 were incubated
with the ubiquitin reaction components along with the detection re-
agents, 1 nM TUBEs, 1 nM Streptavidin-Tb, and 40 nM anti-GST D2.
The assay exhibited dose-dependency at low nanomolar concentra-
tions of E3 ligase with a linear increase in signal over time. This
assay was conducted in the presence of detection reagents during
the enzymatic reaction, allowing for a kinetic evaluation of E3 ligase
activity in real-time. Advantages of the kinetic method over an end
point method such as an ELISA, are shorter analysis time and reduced
effects of interfering substances [17].
4. Discussion
Novel in vitro E3 assays are constantly being sought to improve
the sensitivity and monitor activity under increasingly physiologicalFig. 4. Dose and time dependent E3 ligase activity. Varying concentrations of the E3 li-
gase GST-TRIM25 were incubated with ubiquitylation enzymes along with detection
reagents, 1 nM TUBEs, 1 nM streptavidin-Tb and 40 nM anti-GST D2; and read
kinetically.
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enous in vitro assay for ubiquitin E3 ligases, using Tandem Ubiquitin
Binding Entities (TUBEs). Unlike previous methods we developed
[16], this assay is a kinetic homogenous approach that utilizes
unmodiﬁed ubiquitin. The advancement of this E3 assay format is
that it monitors in real time and is highly adaptive to various E3 en-
zymes and potentially to substrates, allowing drug discovery to pro-
gress for known and emerging E3-mediated disease processes.
Previous experiments demonstrated that Tandem Ubiquitin Bind-
ing Entities (TUBEs) were able to bind polyubiquitin chains selective-
ly with respect to free ubiquitin [7]. Subsequently, we were able to
utilize this observation to develop an E3 ligase platform which
reported dose and time dependent E3 autoubiquitylation in a homog-
enous manner. The utility of the assay platform was extended by the
observation that it can also be used to kinetically determine E3 activ-
ity in real time. For these reasons, we conclude that this assay plat-
form is an effective tool for characterizing autoubiquitylation
activity of many ubiquitin E3 ligases.
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